Company intelligence / Profile preview

Merck & Co.

Rahway, New Jersey, United Statesen.wikipedia.org ↗

Ownership: Public · MRK
Employees: ~68000
Development stage: Commercial

Overview

Merck has a diverse pipeline with multiple commercial products. Their flagship product Keytruda faces patent expiration, but they have seven potential cardiometabolic approvals anticipated by 2030 with peak revenue potential exceeding $15 billion by mid-2030s. Recently approved Winrevair for pulmonary arterial hypertension showed strong efficacy.

Therapeutic areas: OphthalmologyOncologyCardiovascular
Modalities: Small moleculesbiologicsvaccines
Industry: Pharma

Drug pipeline

854 assets

diphtheria, tetanus, pertussis (acellular), measles, mumps, rubella, and varicella vaccine

Approved

853 more assets in the full pipeline.

Request access →

Financials

Market cap: $274.9B
Total revenue: $16.3B
Enterprise value: $318.3B

Beyond the preview

Go deeper on Merck & Co..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Merck & Co..

Explore the full profile